The Minimum Effective Dose (ED90) of Liposomal Bupivacaine for Preserving Motor Function

Launched by AFFILIATED HOSPITAL OF JIAXING UNIVERSITY · Sep 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called bupivacaine liposomes to see how well it can help preserve movement in people who may experience motion sickness. The researchers are particularly interested in finding out the lowest effective dose that still works well for this purpose. The trial is currently looking for participants aged 41 to 65 who are in generally good health, meaning they have no serious ongoing health issues and a body mass index (BMI) between 18 and 35.

To join the study, individuals must not be pregnant, must not have a history of certain medical conditions (like issues with their nervous system), and must be able to understand and consent to participate. If eligible, participants can expect to receive the study treatment and will be monitored closely to see how it affects their movement and overall function. This trial is important as it could lead to better treatments for those dealing with motion sickness while ensuring they can still move freely.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 41-65 years ASA physical condition 1-3 BMI 18-30 kg/m2 undergoing arthroscopic shoulder surgery
• Exclusion Criteria:
• • Inability to consent to the study pregnancy allergy to local anesthetics preexisting neuropathy cervical pathologies (i.e., herniated disc, myelopathy) chronic pain syndromes (defined as reflex sympathetic dystrophy or complex regional pain syndrome) severe respiratory conditions psychiatric or cognitive disorders that prohibit patients from adhering to the study protocol history of drug or alcohol abuse chronic opioid use (longer than 3 months or daily morphine equivalents more than 5mg/day for 1 month) contraindication for general anesthesia and/or interscalene nerve block and planned open shoulder arthrotomies Muscle related diseases